I don’t agree with management being a joke. I feel that

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps bigO #92296
532
I don’t agree with management being a joke. I feel that they have lead us in a very open way. I like the fact that they are pretty transparent and haven’t seen this as a common open information in other stocks. In fact it is just the opposite and you might get information once in a great while in other investments.

Are you wondering what is up with our direction and what we have in play? How many trials we have and what direction we are going for those trials? Do you know the answers to what I just stated. Well, if you pay attention you know everything that CYDY is doing in all facets of every arena we are in. Current trials and location of trials and possible revenue and CSP’s, and everything and anything that is on the agenda for the investor that is in tune with what is going on across the company. That is such a privilege to be “in the know” of what is going on. Nader tells us everything he is allowed to tell us.

Tell me... where else would you as a investor get more information? Granted you could do some due diligence and find out some of the information that is provided by the company but this company just is open beyond all other companies and just flat out tells you so you don’t have to do the searches. Do you feel that any of this information helps you with your investment? I know I do. Information is power as they say. How we use this information is what helps us make our decisions.

I personally don’t want to lose this pipeline of information and clarity that it is provided in. It may not always be perfect but I can judge what is brought foreword just like anyone else. I like the openness of all that is Nader and management. I worry that this investor group is nothing like the management we currently have because they file a notice and then don’t follow up with a plan. It just doesn’t make sense to me. Why file a attack against a company without offering a better plan or direction? It is a sign to me that nothing has been revealed by the 5%er’s because they don’t have a better plan or a direction but want control anyway. That to me is not a reason to attack the company. If you don’t have a top 100 CEO’s to offer than how do we know there would be an improvement over Nader. You can knock Nader in many ways but he has got us to what not only I believe is very close internationally to an approval but the interim trial results might just get us a domino effect in many countries.

We have missed the boat essentially in the USA for Critical patients due to improvements in SOC. We have a big group waiting in LH’s still. But have directed our trials to international paths and how smart was this? Ask yourself as an investor... is it the right time to test drive a new management team that could throw us into a spin of lost time while they try to figure things out and it delays us literally months or a year before they get us to the same place Nader and management can in a few months... for Covid to pan out for us we need it to happen quickly or we will miss the whole pandemic and have lost our first potential revenue. Is now the right time to risk another management team when our team seems like it is just around the corner if we hit interim trial results that look like they are designed much easier than our other trials before this? Some will say we should of done this or that in the protocols of the next two trials but give the benefit of the doubt to the management for what they have learned so far and know that we had direction from a different CRO and another regulator in Brazil’s FDA equivalent.

For me it just seems the wrong time to trust another group. One we don’t know their plan.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 186

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 206

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 183

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 0

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 84

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 166

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading

Top 5 Most Recently Viewed Articles

Tech Stocks Lead Strong Start for June 2024: Nvidia Tops Apple and Records Set

Updated Category Markets Views 296

Today's Monumental Achievements in the Stock Market: S&P 500 and Nasdaq 100 Hit Record Highs, Nvidia Surpasses Apple in Market Value Analyzing Today's Market Milestones Important milestones were hit in today's financial markets, that not only reflect the strength of the market, but point towards changing patterns within the tech industry. Two of the most followed indices,...

Continue Reading
Knight Therapeutics Enhances Collaboration with Helsinn for Onicit®

Updated Category News Views 218

Expansion of Knight Therapeutics and Helsinn Partnership MONTREAL and LUGANO, Switzerland – Knight Therapeutics Inc. (TSX: GUD), a pan-American specialty pharmaceutical company, has taken significant steps to enhance its partnership with Helsinn Healthcare SA, a well-respected global pharmaceutical company. This collaboration will focus on an exclusive license,...

Continue Reading
Community Preparedness Event for Houston Families: Join Us!

Updated Category News Views 149

Empowering Houstonians: A Community Event for Disaster Preparedness Whitestone Developments in collaboration with Empower CDC are taking a remarkable step to ensure families are prepared for emergencies. They are hosting a community event focused on disaster preparedness that promises to be educational and engaging. This initiative, titled "Get Ready, Houston!", aims to...

Continue Reading
Global Collaboration for Sustainable Urban Development in Focus

Updated Category News Views 207

A New Era of Sustainable Urban Development In an inspiring event held on November 1 in Bogota, a significant gathering took place centered around sustainable urban development. This thematic session was part of the 2025 Global Observance of World Cities Day, marking an important milestone in addressing environmental concerns globally. Participation and Significance of the...

Continue Reading
Geotab® Transforming Fleet Management for Government Efficiency

Updated Category News Views 47

Geotab® Enhances Fleet Management with Telematics Solutions Geotab Inc. has taken a significant step towards improving operational efficiency by partnering with the Delaware Department of Transportation (DelDOT). This collaboration aims to leverage data insights and artificial intelligence to boost efficiency and promote sustainability in governmental fleet operations....

Continue Reading